Sari la conținut

Română · beta. Traducerea a fost făcută automat și este încă în curs de revizuire. Citește pagina în engleză

perspectiva aiqbenchSiguranță AI

analiza aiqbench

The primary subject of this article is AI safety and governance, specifically focusing on the development of evaluation benchmarks to prevent rogue models. It centers on a proposed hybrid human-AI judging system as a method to address risks in real-world applications like medicine.
Sursă care acoperăAI Now Institute
Ce este aceastaLectura unui model asupra articolului și a acoperirii conexe, scrisă pentru aiqbench. Nu sunt cuvintele publicației.

Ex-Googlers Are Planning AI-Human Hybrid to Prevent Rogue Models

AI Now Institute1 min de cititArticolul și perspectiva sunt în engleză.

Sarah Myers West, co-executive director of the AI Now Institute, urges that getting the rules right through concrete benchmarks matters most for mitigating risks. The post Ex-Googlers Are Planning AI-Human Hybrid to Prevent Rogue Models appeared first on AI Now Institute.

Some question whether a hybrid human-AI judge is the right solution. Sarah Myers West, co-executive director of the AI Now Institute, a policy research center, said the industry has relied too heavily on general benchmarks. She wants safety researchers to develop evaluations tailored to all the different ways real people use the technology in their daily lives. She noted that in medicine, for instance, a drug isn’t judged as safe across the board — it’s tested as a treatment for a specific illness, dose and type of patient. “What is it that you’re benchmarking if you’re not talking about specific use cases?” she said.

Some question whether a hybrid human-AI judge is the right solution. Sarah Myers West, co-executive director of the AI Now Institute, a policy research center, said the industry has relied too heavily on general benchmarks. She wants safety researchers to develop evaluations tailored to all the different ways real people use the technology in their daily lives. She noted that in medicine, for instance, a drug isn’t judged as safe across the board — it’s tested as a treatment for a specific illness, dose and type of patient.

“What is it that you’re benchmarking if you’re not talking about specific use cases?” she said.

Read the full article here.

Text integral sub licența deschisă a publicației · 213 cuvinte

Subiecte conexe